GREATER COMBINED REDUCTIONS IN HbA_1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.

Rodbard HW, Bellary S, Hramiak I, Seino Y, Silver R, Damgaard LH, Nayak G, Zacho J, Aroda VR

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists13 Mar 2019Cited by 17 (Europe PMC)

PMID30865526DOI10.4158/ep-2018-0444PepBankPUB-30865526

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with T2D, semaglutide 0.5 mg increased combined HbA1c and weight target attainment versus comparators.
In plain wordsIn patients with T2D, more reached both blood sugar and weight targets with semaglutide 0.5 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseCombined HbA1c and weight response
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Composite target attainment
25 to 38%
semaglutide 0.5 mg
Composite target attainment
2 to 23%
comparators
Source sentences
Summary
Significantly greater proportions of subjects achieved the composite endpoint with semaglutide 0.5 (25 to 38%) and 1.0 mg (38 to 59%) versus comparators (2 to 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552601
02HumanNon-randomized trialEfficacy outcome
In patients with T2D, semaglutide 1.0 mg increased combined HbA1c and weight target attainment versus comparators.
In plain wordsIn patients with T2D, more reached both blood sugar and weight targets with semaglutide 1.0 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseCombined HbA1c and weight response
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
Composite target attainment
38 to 59%
semaglutide 1.0 mg
Composite target attainment
2 to 23%
comparators
Source sentences
Summary
Significantly greater proportions of subjects achieved the composite endpoint with semaglutide 0.5 (25 to 38%) and 1.0 mg (38 to 59%) versus comparators (2 to 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552602
03HumanNon-randomized trialEfficacy outcome
In patients with T2D, more achieved ≥1.0% HbA1c reductions with semaglutide 0.5 mg than comparators.
In plain wordsIn patients with T2D, more achieved ≥1.0% HbA1c reductions with semaglutide 0.5 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseHbA1c reduction at least 1.0%
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c response
58 to 77%
semaglutide 0.5 mg
HbA1c response
12 to 68%
comparators
Source sentences
Summary
More subjects treated with semaglutide versus comparators achieved ≥1.0% HbA_1c reductions (58 to 77% and 75 to 83% for semaglutide 0.5 and 1.0 mg versus 12 to 68%) and ≥5.0% weight loss (37 to 46%, 45 to 66% versus 4 to 30%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552603
04HumanNon-randomized trialEfficacy outcome
In patients with T2D, more achieved ≥1.0% HbA1c reductions with semaglutide 1.0 mg than comparators.
In plain wordsIn patients with T2D, more achieved ≥1.0% HbA1c reductions with semaglutide 1.0 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseHbA1c reduction at least 1.0%
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c response
75 to 83%
semaglutide 1.0 mg
HbA1c response
12 to 68%
comparators
Source sentences
Summary
More subjects treated with semaglutide versus comparators achieved ≥1.0% HbA_1c reductions (58 to 77% and 75 to 83% for semaglutide 0.5 and 1.0 mg versus 12 to 68%) and ≥5.0% weight loss (37 to 46%, 45 to 66% versus 4 to 30%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552604
05HumanNon-randomized trialEfficacy outcome
In patients with T2D, more achieved ≥5.0% weight loss with semaglutide 0.5 mg than comparators.
In plain wordsIn patients with T2D, more achieved ≥5.0% weight loss with semaglutide 0.5 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseWeight loss at least 5.0%
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Weight response
37 to 46%
semaglutide 0.5 mg
Weight response
4 to 30%
comparators
Source sentences
Summary
More subjects treated with semaglutide versus comparators achieved ≥1.0% HbA_1c reductions (58 to 77% and 75 to 83% for semaglutide 0.5 and 1.0 mg versus 12 to 68%) and ≥5.0% weight loss (37 to 46%, 45 to 66% versus 4 to 30%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552605
06HumanNon-randomized trialEfficacy outcome
In patients with T2D, more achieved ≥5.0% weight loss with semaglutide 1.0 mg than comparators.
In plain wordsIn patients with T2D, more achieved ≥5.0% weight loss with semaglutide 1.0 mg than comparators.
Peptide
Semaglutide
Outcome
IncreaseWeight loss at least 5.0%
Study
n: not reported in source
Comparator
Placebo or active comparators across SUSTAIN trials
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
Weight response
45 to 66%
semaglutide 1.0 mg
Weight response
4 to 30%
comparators
Source sentences
Summary
More subjects treated with semaglutide versus comparators achieved ≥1.0% HbA_1c reductions (58 to 77% and 75 to 83% for semaglutide 0.5 and 1.0 mg versus 12 to 68%) and ≥5.0% weight loss (37 to 46%, 45 to 66% versus 4 to 30%).
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552606
07HumanNon-randomized trialEfficacy outcome
In patients with T2D, target attainment was significantly higher with semaglutide 1.0 mg than 0.5 mg in four of five trials.
In plain wordsIn patients with T2D, more reached targets with semaglutide 1.0 mg than 0.5 mg in four of five trials.
Peptide
Semaglutide
Outcome
IncreaseTarget attainment by dose
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Proportions of subjects achieving targets were significantly higher with semaglutide 1.0 versus 0.5 mg in four of five trials.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552607
08HumanNon-randomized trialSafety outcome
In patients with T2D, semaglutide was well tolerated with a safety profile similar to other GLP-1 receptor agonists.
In plain wordsIn patients with T2D, semaglutide was well tolerated and had a safety profile similar to other GLP-1 receptor agonists.
Peptide
Semaglutide
Outcome
Not applicableTolerability and safety profile
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Adverse events · Whole body
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Semaglutide was well tolerated, with a safety profile similar to other GLP-1 receptor agonists.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 5,119 subjects with T2D in the phase 3 SUSTAIN 1 through 5 and 7 trials, from 33 countries, were included in this post hoc analysis.
Summary · context
Subjects received subcutaneous semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg).
Summary · context
The main endpoint was a composite of ≥1.0% HbA_1c reduction and ≥5.0% weight loss at end of treatment.
Report a problemFND-3086552608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 6 completed · 6 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204